{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Moderate+to+Severe+Rheumatoid+Arthritis&page=2", "query": { "condition": "Moderate to Severe Rheumatoid Arthritis", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Moderate+to+Severe+Rheumatoid+Arthritis&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-23T17:11:09.436Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02886728", "title": "Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Filgotinib", "type": "DRUG" }, { "name": "Placebo to match filgotinib", "type": "DRUG" }, { "name": "MTX", "type": "DRUG" }, { "name": "Placebo to match MTX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1252, "start_date": "2016-08-08", "completion_date": "2019-05-08", "has_results": true, "last_update_posted_date": "2021-06-01", "last_synced_at": "2026-07-23T17:11:09.436Z", "location_count": 45, "location_summary": "Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 42 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Covina", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02886728" }, { "nct_id": "NCT01408602", "title": "A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "MRC375", "type": "DRUG" }, { "name": "Matching Placebo", "type": "DRUG" }, { "name": "MRC375 150mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Molecular Research Center, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2011-11", "completion_date": "2014-07", "has_results": false, "last_update_posted_date": "2014-05-12", "last_synced_at": "2026-07-23T17:11:09.436Z", "location_count": 19, "location_summary": "Mobile, Alabama • Long Beach, California • Los Alamitos, California + 16 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Edgewater", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01408602" }, { "nct_id": "NCT01198002", "title": "A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "LY2127399", "type": "DRUG" }, { "name": "Placebo Q2W", "type": "DRUG" }, { "name": "Placebo Q4W", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1041, "start_date": "2010-12", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2018-05-08", "last_synced_at": "2026-07-23T17:11:09.436Z", "location_count": 75, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 72 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Paradise Valley", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01198002" }, { "nct_id": "NCT02706951", "title": "A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Methotrexate", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" }, { "name": "Placebo Upadacitinib", "type": "DRUG" }, { "name": "Placebo Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 648, "start_date": "2016-03-23", "completion_date": "2022-08-10", "has_results": true, "last_update_posted_date": "2024-01-30", "last_synced_at": "2026-07-23T17:11:09.436Z", "location_count": 52, "location_summary": "Huntsville, Alabama • Mobile, Alabama • Gilbert, Arizona + 43 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02706951" }, { "nct_id": "NCT01721057", "title": "A Study in Moderate to Severe Rheumatoid Arthritis Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Baricitinib", "type": "DRUG" }, { "name": "cDMARD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 684, "start_date": "2012-12", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2019-09-18", "last_synced_at": "2026-07-23T17:11:09.436Z", "location_count": 48, "location_summary": "Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 45 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01721057" }, { "nct_id": "NCT04539964", "title": "Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Implant Procedure", "type": "PROCEDURE" }, { "name": "Conventional Synthetic DMARD", "type": "DRUG" }, { "name": "Active stimulation", "type": "DEVICE" }, { "name": "Non-active stimulation", "type": "DEVICE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "DEVICE" ], "sponsor": "SetPoint Medical Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "22 Years to 75 Years" }, "enrollment_count": 243, "start_date": "2021-01-11", "completion_date": "2027-10", "has_results": true, "last_update_posted_date": "2026-04-14", "last_synced_at": "2026-07-23T17:11:09.436Z", "location_count": 42, "location_summary": "Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 37 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Covina", "state": "California" }, { "city": "Upland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04539964" }, { "nct_id": "NCT00595413", "title": "Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Placebo matched to atacicept", "type": "DRUG" }, { "name": "Atacicept: with loading dose", "type": "DRUG" }, { "name": "Atacicept", "type": "DRUG" }, { "name": "Adalimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "EMD Serono", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 311, "start_date": "2007-09", "completion_date": "2009-10", "has_results": true, "last_update_posted_date": "2016-02-17", "last_synced_at": "2026-07-23T17:11:09.436Z", "location_count": 1, "location_summary": "Rockland, Massachusetts", "locations": [ { "city": "Rockland", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00595413" }, { "nct_id": "NCT05814627", "title": "Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Upadacitinib", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Upadacitinib Matching Placebo", "type": "DRUG" }, { "name": "Adalimumab Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 487, "start_date": "2023-06-15", "completion_date": "2026-07", "has_results": false, "last_update_posted_date": "2026-01-12", "last_synced_at": "2026-07-23T17:11:09.436Z", "location_count": 85, "location_summary": "Flagstaff, Arizona • Glendale, Arizona • Peoria, Arizona + 75 more", "locations": [ { "city": "Flagstaff", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05814627" }, { "nct_id": "NCT05516758", "title": "A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis", "Arthritis", "Joint Diseases", "Musculoskeletal Diseases", "Rheumatic Diseases", "Connective Tissue Diseases", "Autoimmune Diseases", "Immune System Diseases" ], "interventions": [ { "name": "Peresolimab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 491, "start_date": "2022-08-31", "completion_date": "2025-01-17", "has_results": true, "last_update_posted_date": "2025-12-04", "last_synced_at": "2026-07-23T17:11:09.436Z", "location_count": 54, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Glendale, Arizona + 43 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05516758" }, { "nct_id": "NCT02222493", "title": "A Study of PF-06438179 (Infliximab-Pfizer) and Infliximab in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (REFLECTIONS B537-02).", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "PF-06438179", "type": "BIOLOGICAL" }, { "name": "Infliximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 650, "start_date": "2014-08-26", "completion_date": "2017-06-01", "has_results": true, "last_update_posted_date": "2018-05-30", "last_synced_at": "2026-07-23T17:11:09.436Z", "location_count": 43, "location_summary": "Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 34 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02222493" } ] }